LA JOLLA, Calif., March 27, 2015 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX), a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that data from the completed Phase 3 registration clinical trial evaluating the company's investigational new drug SD-809 (AustedoTM) in chorea associated with Huntington's disease has been accepted for presentation at the 67th American Academy of Neurology (AAN) Annual Meeting taking place April 18-25, 2015 in Washington, DC. The results will be presented by Samuel A. Frank, M.D., associate professor of neurology, Boston University School of Medicine and principal investigator for the study, known as First-HD.
Following are details about the presentation:
|Title: First Time Use of SD-809 in Huntington Disease (First-HD)|
|Session Name: Emerging Science Session|
|Date and Time: April 22, 2015, 6:15 PM - 7:45 PM|
|Location: Walter E. Washington Convention Center, Washington, DC|
First-HD is a randomized, double-blind, placebo-controlled, parallel-group trial of Austedo in 90 individuals with chorea associated with Huntington's disease. The 12-week trial was designed to evaluate and generate label information for the safety, tolerability and efficacy of Austedo for potentially treating chorea associated with Huntington's disease. The company is on track to submit a New Drug Application (NDA) with the FDA by mid-2015.
About Auspex Pharmaceuticals
Auspex Pharmaceuticals is a late-clinical stage biopharmaceutical company dedicated to developing innovative medicines for hyperkinetic movement disorders and other rare diseases. Auspex employs its proprietary technology to create patent-protected, new chemical entities from known, clinically proven therapies. The company's lead product, Austedo (SD-809), is in final stages of development for the treatment of chorea associated with Huntington's disease, a neurodegenerative movement disorder that impacts cognition, behavior and movements. In addition, Auspex is investing in the broad potential of Austedo for the treatment of other movement disorders, including tardive dyskinesia and tics associated with Tourette syndrome. The company's pipeline also includes SD-560, being developed for fibrotic conditions, and SD-1077, which is being developed for Parkinson's disease. For further information, please visit the company's website www.auspexpharma.com.
CONTACT: Corporate Communications Contacts: For Media: Dan Budwick, Pure Communications, Inc. firstname.lastname@example.org (973) 271-6085 For Investors: Monique Allaire Lyons, Pure Communications, Inc. email@example.com (781) 631-0759
Source:Auspex Pharmaceuticals, Inc.